Vifor Pharma AG (OTCMKTS:GNHAY)’s share price traded up 9.7% on Wednesday . The stock traded as high as $28.36 and last traded at $28.36. 104 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 546 shares. The stock had previously closed at $25.86.
Several analysts have weighed in on the company. Barclays reissued an “equal weight” rating on shares of Vifor Pharma in a report on Monday, June 28th. JPMorgan Chase & Co. raised Vifor Pharma from an “underweight” rating to a “neutral” rating in a report on Wednesday, April 7th. Finally, UBS Group restated a “neutral” rating on shares of Vifor Pharma in a research report on Monday, March 29th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock has an average rating of “Hold”.
The company’s 50-day simple moving average is $27.57.
Vifor Pharma AG is a pharmaceutical company, which engages in the research, development, production, and marketing of therapeutic products. It operates through the following geographical segments: Switzerland, Europe, USA, Rest of World, and Group. The firm offers products for iron deficiency, nephrology, and cardio-renal therapies.
Further Reading: What is a blue-chip stock?
Receive News & Ratings for Vifor Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vifor Pharma and related companies with MarketBeat.com's FREE daily email newsletter.